Welcome to our dedicated page for Bon Natural Life news (Ticker: BON), a resource for investors and traders seeking the latest updates and insights on Bon Natural Life stock.
Bon Natural Life Limited (BON) maintains its position as an innovator in plant-based solutions for health and personal care markets. This comprehensive news hub provides stakeholders with essential updates on the company's operational developments, product innovations, and strategic initiatives.
Investors and industry observers will find timely updates covering financial results, production capacity expansions, and quality certifications. The resource particularly tracks BON's emerging presence in the spirits market through its Jiangwang’s spirits distribution partnership.
Key updates include developments from BON's R&D center, progress at their Yumen production facility, and international market expansions. All content is vetted for relevance to investment analysis and market trend monitoring.
Bookmark this page for streamlined access to BON's corporate announcements, regulatory filings, and market positioning updates. Check regularly for insights into the company's growth in natural product sectors and emerging business verticals.
Bon Natural Life Limited (BON) has announced a non-exclusive sales cooperation agreement with Shanghai Risesun International Trade for marketing and distributing BON's tea pigment series health products in China. The agreement spans 24 months with a total contract value of $24 million.
The company's tea pigments, which offer benefits in lipid modulation, glycemic control, antioxidant activity, and anti-peptic ulcer properties, are targeting the digestive wellness and blood glucose regulation markets. With strong market fundamentals and global tea popularity, the venture has potential to reach a $1 billion market valuation.
Bon Natural Life Limited (BON) has announced an exclusive cooperation agreement with Beijing Huahai Keyuan for the distribution of its postbiotic hypoglycemic ingredients. The agreement spans 36 months with a contract value of $32 million. BON's patented product is designed to regulate blood sugar and control post-meal glucose spikes, offering advantages in safety and convenience.
The company is targeting the postprandial blood glucose control market, which has a size of over $30 billion and maintains a 7.5% compound annual growth rate. BON expects significant market advancement and growth in sales and profits over the next 2-3 years through this product line.
Bon Natural Life Limited (BON) has announced a 1-for-25 reverse stock split effective May 19, 2025, at 12:01 a.m. Eastern Time. The reverse split is primarily aimed at maintaining Nasdaq listing compliance by meeting the $1.00 minimum bid price requirement. Following the split, each 25 existing Class A ordinary shares will be consolidated into one new share, with fractional shares rounded up.
The company will maintain its "BON" trading symbol on Nasdaq with a new CUSIP number G14492204. Additionally, BON's authorized share capital will increase to 1 billion Class A ordinary shares, 50 million Class B shares, and 50 million preference shares. The Class B shares' conversion ratio to Class A shares will change from 1:1 to 1:25.
BON Natural Life Limited (Nasdaq: BON) has announced the launch of its innovative sleep health product series, featuring a patent-pending "Glucoraphanin-Myrosinase" delivery system. This breakthrough technology aims to enhance the bio-availability of glucoraphanin, a key compound found in broccoli that converts to sulforaphane in the body.
The company's proprietary system addresses the inefficient enzymatic conversion of glucoraphanin to sulforaphane, which typically limits the body's ability to access broccoli's full health benefits. Sulforaphane is associated with multiple health advantages, including sleep regulation, anti-cancer properties, and neuro-protective effects.
CEO Yongwei Hu emphasizes that BON's new sleep health products are designed to outperform traditional formulations through superior bio-availability and enhanced biological potency, positioning the company to capitalize on market opportunities in the sleep health sector.
Bon Natural Life (BON) has secured a significant $12 million 24-month supply agreement with Shanghai Yunsheng to co-develop apple polyphenol-infused health solutions. The partnership focuses on combining BON's patented extraction technology for antioxidant-rich apple polyphenols with plant-based proteins.
The initiative targets multiple health benefits including weight management, metabolic health, lipid management, and reduction of age-related muscle atrophy. Market validation shows similar apple polyphenol blends generating $40 million in recurring revenue, with monthly sales exceeding 500,000 units.
BON aims to capitalize on this high-growth market through dual revenue streams: standalone nutraceuticals and functional food additives, while maintaining strong profit margins.
Bon Natural Life (Nasdaq: BON) has announced a breakthrough in broccoli-derived nutrition with their patent-pending Glucoraphanin-Myrosinase co-delivery system. This biotech innovation enhances the bio-activity of glucoraphanin, a key compound in broccoli that converts to sulforaphane.
The technology addresses the previously inefficient conversion process of glucoraphanin to sulforaphane, which is known for its anti-cancer, sleep improvement, neuroprotective, digestive enhancement, anti-inflammatory, antioxidant, and anti-aging properties. The company's solution ensures optimal enzymatic activation within the body, achieving higher conversion efficiency to bio-active sulforaphane.
The product is scheduled for market entry in Q2 2025, targeting the functional foods and beverages sector. The company positions this innovation as a potential catalyst for expanding the broccoli-derived wellness market, with applications across multiple sectors including anti-tumor therapies, mental health support, and digestive health management.
Bon Natural Life (Nasdaq: BON) has announced a significant breakthrough in tea pigments bio-manufacturing technology between October 2024 and January 2025. The company achieved an industry-leading yields rate of 12-16% with purity levels exceeding 95%.
Tea pigments demonstrate important biological properties including lipid-lowering, blood glucose reduction, antioxidant effects, and anti-peptic ulcer capabilities. The compound is considered the most promising functional tea derivative since tea polyphenols commercialization, particularly for digestive wellness and blood glucose applications.
The global tea pigment industry is projected to exceed $12 billion by 2025. BON plans to pursue innovative formulations of tea pigments-based products through strategic partnerships, focusing on gastrointestinal and metabolic health applications.
Bon Natural Life (Nasdaq: BON) has announced the upcoming launch of a revolutionary patent for a natural postbiotic ingredient targeting blood sugar regulation. The food-derived formula demonstrates significant efficacy in glycemic management, reducing post-meal blood sugar spikes by 15-30% within 1-3 hours when consumed 10-30 minutes before meals.
The solution outperforms existing market alternatives while offering key advantages including food safety and ease of use, factors contributing to high user compliance. The company is pursuing an aggressive global patent protection strategy over the next two years across major markets, aiming to secure their position in the metabolic health sector.
FAQ
What is the current stock price of Bon Natural Life (BON)?
What is the market cap of Bon Natural Life (BON)?
